Ultima Pharma Steroid Shop

Ultima-DSIP 2 

0/5

$60.00

Support

info@getroids1.net
Write to us for more information about this product.

Shipping

SHIPPING COST : $35 (Delivery Time: 5-7 Days)

Payment Methods

Bitcoin Zelle Western Union Money Gram CashApp Bank Transfer

Description

Active substance : Delta Sleep-inducing Peptide

WHAT IS DELTA SLEEP-INDUCING PEPTIDE?

Delta sleep-inducing peptide (DSIP) is a nonapeptide with somnogenic properties that influence neuromodulation. Predominantly found in the brain, DSIP readily crosses the blood-brain barrier. Research classifies DSIP and its analogs as peptide neuromodulators.

Studies have revealed that DSIP exhibits stress-protective actions, aiding in the reduction of stress-related metabolic disorders in both humans and animals. It is believed that DSIP modulates the activity of GABAergic and glutamatergic neuronal systems.

CONTENT AND POTENCY:

DSIP is available in a concentration of 1mg/mL for subcutaneous injection, provided in a 3mL vial.

SUGGESTED DOSAGE:

The suggested dosage for DSIP is a subcutaneous injection of 0.1mL once daily at bedtime.

RESEARCH ON DELTA SLEEP-INDUCING PEPTIDE:

DSIP was originally isolated from rabbits in 1977. It is a nonpeptide synthesized in the hypothalamus and targets various sites including the brainstem.

As its name implies, DSIP promotes sleep, which has been demonstrated in rabbits, mice, rats, cats, and humans. It induces a type of sleep characterized by an increase in delta rhythm on EEG.

Numerous studies have shown that low doses of DSIP promote sleep in various species. Although its physiological role requires further clarification, DSIP exhibits characteristics typical of brain peptides, including a bell-shaped dose-response curve, central effects after peripheral administration, a delayed and prolonged time course, and intact penetration of the blood-brain barrier.

One study examined the effects of DSIP on 16 insomniac patients over five consecutive nights in a laboratory setting. After receiving DSIP or a placebo during the afternoon of the third, fourth, and fifth nights, objective and subjective measures of sleep quality and tiredness were evaluated. The results indicated improved objective sleep quality and decreased tiredness in the DSIP group compared to the placebo group. However, further data analysis suggested that the observed effects may have been influenced by changes in the placebo group, leading to the conclusion that short-term treatment of chronic insomnia with DSIP may not provide significant therapeutic benefits.

Ultima-DSIP KEY FEATURES:

High-quality raw materials

 

2 ml sterile vial

Note: This product is shipped worldwide from the USA domestically and from the Asian continent.